CLINICAL_TRIALS
trial_result
· 2024-12-27
Clinical Trial Update: Study of ALXN1850 in Participants With Hypophosphatasia (HPP) [Phase 1]
Summary
Phase 1 trial of ALXN1850 in hypophosphatasia has completed, and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Hypophosphatasia | Phase 1 | Status: COMPLETED | Results posted: 2024-12-27